Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) Director Jason Aryeh sold 700 shares of the company’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $320.43, for a total value of $224,301.00. Following the completion of the sale, the director directly owned 108,758 shares in the company, valued at approximately $34,849,325.94. The trade was a 0.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Jason Aryeh also recently made the following trade(s):
- On Friday, October 30th, Jason Aryeh sold 1,411 shares of Ligand Pharmaceuticals stock. The stock was sold at an average price of $320.24, for a total value of $451,858.64.
Ligand Pharmaceuticals Stock Performance
Shares of Ligand Pharmaceuticals stock opened at $299.00 on Friday. Ligand Pharmaceuticals Incorporated has a 12 month low of $175.89 and a 12 month high of $326.63. The firm has a market capitalization of $5.98 billion, a P/E ratio of 133.48, a P/E/G ratio of 5.52 and a beta of 1.16. The company has a current ratio of 1.22, a quick ratio of 30.96 and a debt-to-equity ratio of 0.71. The business has a fifty day simple moving average of $298.38 and a two-hundred day simple moving average of $254.61.
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The biotechnology company reported $2.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.33 by $0.34. Ligand Pharmaceuticals had a net margin of 20.27% and a return on equity of 5.22%. The company had revenue of $78.75 million during the quarter, compared to analyst estimates of $77.00 million. During the same period last year, the business earned $3.09 EPS. Ligand Pharmaceuticals’s quarterly revenue was down 31.8% compared to the same quarter last year. On average, equities analysts forecast that Ligand Pharmaceuticals Incorporated will post 2.35 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several research firms have recently issued reports on LGND. Weiss Ratings lowered shares of Ligand Pharmaceuticals from a “buy (b)” rating to a “hold (c)” rating in a report on Monday. Barclays began coverage on Ligand Pharmaceuticals in a research report on Friday, September 25th. They issued an “overweight” rating and a $345.00 price target on the stock. Royal Bank Of Canada upped their price target on Ligand Pharmaceuticals from $345.00 to $357.00 and gave the stock an “outperform” rating in a research note on Friday, October 30th. Bank of America raised their price objective on Ligand Pharmaceuticals from $266.00 to $388.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. Finally, Leerink Partners assumed coverage on Ligand Pharmaceuticals in a research note on Friday, August 14th. They set an “outperform” rating and a $330.00 price objective for the company. Nine research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $339.78.
Check Out Our Latest Stock Analysis on Ligand Pharmaceuticals
Hedge Funds Weigh In On Ligand Pharmaceuticals
A number of hedge funds have recently bought and sold shares of LGND. Maryland State Retirement & Pension System raised its holdings in Ligand Pharmaceuticals by 51.7% in the 3rd quarter. Maryland State Retirement & Pension System now owns 4,433 shares of the biotechnology company’s stock worth $1,385,000 after acquiring an additional 1,510 shares during the last quarter. Jacobi Capital Management LLC purchased a new stake in Ligand Pharmaceuticals during the 3rd quarter valued at $31,000. Jefferies Financial Group Inc. purchased a new stake in Ligand Pharmaceuticals during the 3rd quarter valued at $1,335,000. Illinois Municipal Retirement Fund boosted its stake in Ligand Pharmaceuticals by 4.7% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 10,144 shares of the biotechnology company’s stock valued at $3,169,000 after purchasing an additional 453 shares during the last quarter. Finally, Lido Advisors LLC increased its holdings in shares of Ligand Pharmaceuticals by 11.6% in the 3rd quarter. Lido Advisors LLC now owns 2,809 shares of the biotechnology company’s stock worth $877,000 after purchasing an additional 292 shares in the last quarter. Institutional investors own 91.28% of the company’s stock.
More Ligand Pharmaceuticals News
Here are the key news stories impacting Ligand Pharmaceuticals this week:
- Positive Sentiment: Citigroup raised its price target to $402 from $397 and maintained a Buy rating, implying substantial upside from the referenced $299 share price. Citigroup analyst coverage
- Positive Sentiment: HC Wainwright raised its Q4 2026 EPS estimate to $2.50 from $2.11 and reiterated its Buy rating. HC Wainwright estimates
- Neutral Sentiment: Ligand’s latest reported quarter beat EPS and revenue expectations, though revenue fell 31.8% year over year, a mixed fundamental backdrop for investors.
- Negative Sentiment: HC Wainwright sharply lowered its FY2026 EPS estimate to $2.88 from $5.02 and cut FY2027 to $7.15 from $7.90. Those reduced full-year forecasts may offset the improved Q4 outlook. HC Wainwright estimates
- Negative Sentiment: Insider Andrew Reardon sold 5,000 shares, reducing his holdings by 13.57%; the transaction was under a pre-arranged Rule 10b5-1 plan. Director Jason Aryeh also sold shares, including 700 on November 2, though that sale represented a small reduction in his holdings. Insider transactions
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is a biopharmaceutical company that develops, acquires and licenses technologies intended to improve the development and commercialization of medicines. Rather than operating primarily as a traditional drug manufacturer, Ligand generally works with pharmaceutical and biotechnology partners, receiving licensing payments, royalties and other consideration tied to partnered products.
The company’s principal technology is Captisol, a modified cyclodextrin designed to improve the solubility, stability and delivery of certain active pharmaceutical ingredients.
Featured Articles
- Five stocks we like better than Ligand Pharmaceuticals
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
